Shire secures Cinryze supply with tech transfer to Austria

By Flora Southey

- Last updated on GMT


Related tags Blood Immune system Pharmaceutical drug

The US FDA has approved Shire’s request to make rare genetic disease treatment Cinryze at its manufacturing facility in Vienna.

Cinryze (C1 esterase inhibitor [human]) is an injectable medicine derived from human plasma used to help prevent swelling and/or painful attacks in patients with the rare genetic disease Hereditary Angioedema (HAE).

Manufacture of the drugs requires a series of precipitation, filtration and chromatography steps.

Shire will continue​ to employ Dutch contract manufacturing organisation (CMO) Sanquin Blood Supply to make Cinryze, and said the technology transfer adds a second production source for the drug to ensure supply meets patient demand.

 “Internalising the production of Cinryze adds a second source for the product and thereby reduces any risks to supply for the HAE patients who count on Cinryze to prevent attacks,” ​a spokesperson told us.

Production at the Vienna facility will begin in the first quarter of 2018.

Last month, Shire requested​ the US Food and Drug Administration’s (FDA) permission to transfer technology to make Gammagard Liquid – a plasma-derived antibody product used to treat primary humoral immunodeficiency (PI) – at its facility in Covington, Georgia.

Related news

Show more

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers

Follow us


View more